Evaluation of Therapeutic Drug Monitoring Services in Tangerang X Hospital
Abstract
Therapeutic Drug Monitoring (TDM) is a clinical practice to increase the effectiveness of therapy and minimize the risk of adverse drug reactions (ADR). The purpose of this study is to describe the implementation of TDM, and whether it is in accordance with the Regulation of the Minister of Health of the Republic of Indonesia (Permenkes) Number 72 of 2016 concerning pharmaceutical service standards at hospitals and the evaluation of TDM services conducted by pharmacists on inpatients. This research covers a descriptive study with a collection of retrospective data from TDM documents of inpatients during the period of January–May 2016 at X Hospital, Tangerang. The implementation of TDM by pharmacists based on the standards was 73%. The number of patients who met the inclusion criteria were 50 patients. Based on the diagnosis of the disease, patients with the potential of receiving TDM were patients with hypertension (10 patients; 20%), congestive heart failure (9 patients; 18%), and diabetes mellitus (8 patients; 16%). Whereas patients with both potential drug interaction and prescribed with more than 10 drugs was 29 patients (58%), patients with both potential drug interaction and diagnosed with three types of diseases was 19 patients (38%). The implementation of TDM in accordance with pharmaceutical service standards requires the competence of clinical pharmacist pharmacists with 2 years work experience. Potential drug interactions can be controlled by prioritizing TDM based on the number of drugs, complications of the disease and type of disease.
References
2. Jason Lazarou et al. Incidence of adverse drug reactions in hospitalized patients. JAMA, Volume 279 no 15 April 1998 dan J. Simon Bell, et al drug related problems in the community setting, download from www.medscape.com 24/05/2009
3. Departemen Kesehatan Republik Indonesia. Pedoman Pemantauan Terapi Obat. Jakarta: DepKes RI; 2009
4. Maher RL, Hanlon JT, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014; 13(1):57–65. doi: 10.1517/14740338.2013.827660
5. Abe, J., Umetsu, R., Uranishi, H., et all. Analysis of Polypharmacy Effects in Older Patients using Japanese Adverse Drug Event Report Database. e0190102. PLoS One; 2017. 12(12).
6. Ahmed, B., Nanji, K., Mujeeb, R. & Patel, M. J. Effects of Polypharmacy on Adverse Drug Reactions among Geriatric Outpatients at a Tertiary Care Hospital in Karachi. e112133. A Prospective Cohort Study: PLoS One; 2014. 9(11),
7. American Pharmacist Association. 2012. Monitoring Drug Therapy: Three Steps for Pharmacist. American Pharmacist Association. URL https://pharmacist.com/monitor ing-drug-therapy-three-steps-pharmacists (accessed 23.3.18)
8. Coleman, J. J., Ferner, R. E. & Evans, S. J. W. Monitoring for adverse drug reaction. 61(4). British Journal of Clinical Pharmacology; 2009. 371-378.
9. Farias, T. F., Aguiar, K. S., Rotta, I., Belletti, K. M. S. & Carlotto, J., Implementing a clinical pharmacy service in hematology. 14(3). Einstein: Sao Paulo; 2016. 384-390.
10. Kang, J. S. & Lee, M. H. Overview of Therapeutic Drug Monitoring. 24(1). Korean Journal of Internal Medicine; 2009.1-10.
11. Kannan, B., Nagella, A. B., Prabhu, A. S., Sasidharan, G. M., Ramesh, A. S. & Madhugiri, V. Incidence of Potential Drug-Drug Interactions in a Limited and Stereotyped Prescription Setting – Comparison of Two Free Online Pharmacopoeias. e886. Cureus Journal of Medical Science; 2016. 8(11),
12. Lombardi, N., Wei, L., Ghaleb, M., Pasut, E., Leschiutta, S., Rossi, P. & Troncon, M. G. Evaluation of the implementation of a clinical pharmacy service on an acute internal medicine ward in Italy. 18. BMC Health Services Research; 2018. 289.
13. Saddique, A. A. Development of Clinical Pharmacy services at King Khalid Univesity Hospital and its impact on the quality of healthcare provided. 20(3). Saudi Pharmaceutical Journal; 2012. 273-277.
14. Talasaz, A. H. The Potential Role of Clinical Pharmacy Services in Patients with Cardiovascular Diseases. 7(2). The Journal of Tehran University Heart Center; 2012. 41-46.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Tools
